Evotec CEO Werner Lanthaler resigns; After Novo deal, ex-Forma chief ushers in new era at Pacira
→ Werner Lanthaler announced his resignation as CEO of serial Big Pharma partner Evotec on Wednesday, and his former COO Mario Polywka will fill in as interim chief until a permanent successor is named. Under Lanthaler’s leadership, Evotec has formed alliances with Takeda (RNA), Bristol Myers Squibb (neuro diseases), Eli Lilly (metabolic diseases) and Novo Nordisk (kidney diseases), among many others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.